Effects of oral epigallocatechin gallate on the oral pharmacokinetics of verapamil in rats

Biopharmaceutics and Drug Disposition

Volumn 30, Issue 2, 2009, Pages 90-93

  Chung, Joong Hwa ^a   Choi, Dong Hyun ^a   Choi, Jun Shik ^a  

^a Chosun University   (South Korea)

Author keywords

CYP3A subfamily; Epigallocatechin gallate (EGCG); P gp; Pharmacokinetics; Rats; Verapamil and norverapamil

Indexed keywords

CYTOCHROME P450 3A; EPIGALLOCATECHIN GALLATE; NORVERAPAMIL; VERAPAMIL; ANTIOXIDANT; CALCIUM CHANNEL BLOCKING AGENT; CATECHIN; DRUG DERIVATIVE; GLYCOPROTEIN P;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG POTENTIATION; ENZYME INHIBITION; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION; ANIMAL; BIOAVAILABILITY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG INTERACTION; METABOLISM; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTIOXIDANTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CALCIUM CHANNEL BLOCKERS; CATECHIN; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; MALE; P-GLYCOPROTEIN; RATS; RATS, SPRAGUE-DAWLEY; VERAPAMIL;

EID: 63049135772     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.644     Document Type: Article

References (18)

1. Thummel KE, Shen DD, Isoherranen N, Smith HE. Appendicts II. Design and optimization of dosage regimens; pharmacokinetic data. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics, Brunton LL, Lazo JS, Parker KL (eds), 11th edn. McGraw-Hill, Medical Publishing Division: New York, 2006; 1884.
2. Walles M, Thum T, Levsen K, Borlak J. Metabolism of verapamil 24 new phase I and phase II metabolites identified in cell cultures of rat hepatocytes by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 798: 265-274.
3. Tracy TS, Korzekwa KR, Gonzalez FJ, Wainer IW. Cytochrome P450 isoforms involved in metabolism of the enantiomers of verapamil and norverapamil. Br J Clin Pharmacol 1999; 47: 545-552.
4. Lewis DFV. P450. Substrate specificity and metabolism. In: Cytochromes P450. Structure, Function, and Mechanism. Taylor & Francis: Bristol, 1996; 122.
5. Adachi Y, Suzuki H, Sugiyama Y. Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res 2001; 18: 1660-1668.
6. Pauli-Magnus C, von Richter O, Burk O et al., Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein. J Pharmacol Exp Ther 2000; 293: 376-382.
7. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Ann Rev Biochem 1993; 62: 385-427.
8. Chu DC, Juneja LR. General chemical composition of green tea and its infusion. In: Chemistry and Application of Green Tea, Yamamoto T, Juneja LR, Chu DC, Kim M (eds). CRC Press: New York, 1997; 13-22.
9. Muto S, Fujita K, Yamazaki Y, Kamataki T. Inhibition by green tea catechins of metabolic activation of procarcinogens by human cytochrome P450. Mutat Res 2001; 479: 197-206.
10. Jodoin J, Demeule M, Beliveau R. Inhibition of the multidrug resistance P-glycoprotein activity by green tea polyphenols. Biochim Biophys Acta 2002; 1542: 149-159.
11. Kitagawa S, Nabekura T, Kamiyama S. Inhibition of P-glycoprotein function by tea catechins in KBC2 cells. J Pharm Pharmacol 2004; 56: 1001-1005.
12. Lin LC, Wang MN, Tseng TY, Sung JS, Tsai TH. Pharmacokinetics of (-)-epigallocatechin-3-gallate in conscious and freely moving rats and its brain regional distribution. J Agric Food Chem 2007; 55: 1517-1524.
13. LinksHenning SM, Niu Y, Liu Y, et al. Bioavailability and antioxidant effect of epigallocatechin gallate administered in purified form versus as green tea extract in healthy individuals. J Nutr Biochem 2005; 16: 610-616.
14. Ullmann U, Haller J, Bakker GC, Brink EJ, Weber P. Epigallocatechin gallate (EGCG) (TEAVIGO) does not impair nonhaem-iron absorption in man. Phytomedicine 2005; 12: 410-415.
15. Lemos C, Peters GJ, Jansen G, Martel F, Calhau C. Modulation of folate uptake in cultured human colon adenocarcinoma Caco-2 cells by dietary compounds. Eur J Nutr 2007; 46: 329-336.
16. Choi JS, Han HK. The effect of quercetin on the pharmacokinetics of verapamil and its major metabolite, norverapamil, in rabbits. J Pharm Pharmacol 2004; 56: 1537-1542.
17. Chiou WL. Critical evaluation of potential error in pharmacokinetic studies using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 1978; 6: 539-549.
18. Pang KS, Morris ME, Sun H. Formed and preformed metabolites: facts and comparisons. J Pharm Pharmacol 2008; 60: 1247-1275.